Merck held a briefing to outline its R&D strategy following the completion of the Schering-Plough merger. The company provided a review of its late-stage pipeline, commercial strategy, as well as its growth strategy. “This merger was about creating a new global health care leader, and we are well on our way,” said chairman and chief executive officer, Richard T. Clark. “Today’s Merck has excellent capabilities across pharmaceuticals, vaccines and biologics; a robus...